New research can improve heart health

Danish researchers from the University of Copenhagen and Rigshospitalet have shown that people with variation in a gene that inhibits a specific protein in the blood – the so-called apolipoprotein C3 – have a significantly lower level of normal blood lipids than people without this gene variation. Furthermore, the same individuals also have a 41 per cent lower risk of arteriosclerosis.

The research is highly relevant as at least one pharmaceutical company has a drug in the pipeline which inhibits precisely apolipoprotein C3, says Anne Tybjærg-Hansen, Chief Physician at Rigshospitalet and Clinical Professor at the Faculty of Health and Medical Sciences, University of Copenhagen.

The scientific results are based on two of the world's largest population studies, the Copenhagen City Heart Study and the Copenhagen General Population Study, with a total 75,725 participants who were followed for 34 years. The results have just been published in the renowned New England Journal of Medicine.

By using genetic studies that mimic medical inhibition of apolipoprotein C3, we have demonstrated that the protein plays an important role in lowering the level of normal and thus the risk of cardiovascular disease. People with lifelong hereditary inhibition of the protein have very low (less than 1 mmol per litre of ) as well as a significantly reduced risk of cardiovascular disease, says Anne Tybjærg-Hansen.

Need for better treatment

The primary objective of drugs which prevent is to lower . But even among patients whose cholesterol levels are treated to target, there is still a residual cardiovascular risk. Triglycerides are lipids that are carried in the blood, the majority of which come from the food we eat. Triglycerides primarily serve as energy reserves for the body. However, high triglyceride levels in the blood, increase the risk of heart attack and arteriosclerosis.

Medical inhibition of proteins which increase the level of triglycerides is therefore an obvious target for new drugs, concludes Anne Tybjærg-Hansen.

add to favorites email to friend print save as pdf

Related Stories

Danish researchers predict risk of valvular heart disease

Nov 13, 2013

Researchers at the University of Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link between narrowed heart valves and a special lipoprotein in the blood. In the long term, the research ...

Prostate cancer and blood lipids share genetic links

Apr 30, 2014

Numerous studies have suggested a relationship between cardiovascular disease risk factors and prostate cancer. A new study by researchers at the University of California, San Diego School of Medicine, with colleagues in ...

Recommended for you

An autoimmune response may contribute to hypertension

10 hours ago

High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease. Inflammation is thought to promote the development of high blood pressure, though it is not clear what triggers ...

Results of RIBS IV trial reported

Sep 16, 2014

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided superior late angiographic results ...

Results of DKCRUSH-VI trial reported

Sep 16, 2014

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial ...

Results of IVUS-CTO trial reported at TCT 2014

Sep 16, 2014

A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous ...

User comments